

EXELGYN SPONSORED RESEARCH GRANT IN PARTNERSHIP WITH THE INTERNATIONAL FEDERATION OF PROFESSIONAL ABORTION AND CONTRACEPTION ASSOCIATES (FIAPAC)

“Improving the quality of life for women having a medical abortion”

OPEN CALL FOR GRANT PROPOSALS

General Conditions

▼ Sponsor background

Exelgyn is a global pharmaceutical company specialised in women’s healthcare. Its mission is to further improve healthcare for women worldwide and giving them more autonomy. Since Mifegyne® was launched in 1988, Exelgyn has been strongly committed to medical termination of pregnancy and continues striving to ensure women worldwide have access to this safe and effective method. Mifegyne® is approved in more than thirty countries, which has enabled millions of women to terminate their unwanted pregnancy safely and effectively.

Exelgyn is committed to support both healthcare professionals and women throughout each step of a medical termination of pregnancy. Exelgyn is dedicated to research to further improve the treatment process and give women more autonomy.

▼ FIAPAC endorsement

FIAPAC is an international federation of professional abortion and contraception associates whose aims are:

- ▶ Freedom for all women to decide whether to remain pregnant or not.
- ▶ Providing women with access to the best medical techniques available, when and if they opt for abortion.
- ▶ Providing women with psychological and/or social support relating to abortion - where necessary and appropriate.
- ▶ Supporting women and men in informed choices concerning contraception.

- ▶ Maintaining the highest possible standards in abortion practice and providing contraception, without commercial intent.

FIAPAC is grateful to Exelgyn for this independent research grant that will support the successful member(s) in conducting research in a field that has very limited funding available.

▼ Objective and scope

This research grant aims at promoting clinical research and best practice in the management of Termination of Pregnancy (ToP), that improve the quality of life and the autonomy for women before, during and after ToP. This includes but is not limited to:

- ▶ Tolerance management and optimization with first trimester medical abortion
- ▶ Pharmaco-eco aspects of first trimester medical vs. surgical abortion
- ▶ Improvement of women's autonomy
- ▶ Per os administration of misoprostol
- ▶ Medical abortion beyond first trimester for medical reasons

The project must comply with the local Summary of Product Characteristics of the mifepristone.

▼ Grant amount

This grant includes financial assistance amounting to a total of 10,000 euros and professional medical writing assistance for English manuscript preparation. This manuscript will be submitted to an international, peer reviewed journal.

The Exelgyn/FIAPAC Grant Committee may decide to award this sum either in total to fund one project, or separately for two projects.

The award will be paid to an organisation (private, public, research, hospital). It is the beneficiary's responsibility to declare the amount received according to local employment and fiscal regulations.

▼ Eligible applicants

This grant is open to any Healthcare Professional involved in ToP such as gynaecologists, general practitioners or midwives either registered or in training.

They should be paid -up members of the FIAPAC.

▼ Admissibility requirements

Each candidate must provide a complete dossier containing the following items:

- ▶ A current curriculum vitae (in English) - max 2 sides of A4
- ▶ A letter certifying senior staff agreement, if appropriate
- ▶ A filled-in grant application form (see template)

By submitting this application, the applicant agrees to follow the below rules:

- ▶ Inform the Exelgyn/FIAPAC Grant Committee of all other financial resources, either applied for or obtained.
- ▶ Present the research results at the 2024 FIAPAC congress.
- ▶ Inform the sponsor of the project's progress by means of written interim reports every 6 months.
- ▶ Inform the sponsor and Scientific Board of the final results before external communication.
- ▶ Declare all support provided by Exelgyn /FIAPAC in any communication or publication.
- ▶ Provide a detailed budget of the allocated grant.

▼ EXELGYN/FIAPAC Grant Committee

The Exelgyn /FIAPAC Grant Committee is composed of:

- ▶ Christian Fiala (Vienna, Austria)
- ▶ Aubert Agostini (Marseille, France)
- ▶ Teresa Bombas (Porto, Portugal)
- ▶ Kristina Gemzell Danielsson (Stockholm, Sweden)
- ▶ Marek Lubusky (Olomouc, Czech Republic)
- ▶ Mirella Parachini (Roma, Italy)
- ▶ Medical advisor (on behalf of Nordic Pharma)

In the event that the project is submitted by a fellow working together with one member of this board, the member of the board will not participate in the discussion regarding this project.

The eligibility and the awards are determined at the sole discretion of the Exelgyn/FIAPAC Grant Committee. All decisions made by the EXELGYN/FIAPAC Grant Committee are final and are not subject to appeal. No reason for failure to award will be given.

▼ Submission

- ▶ The applications must be sent in English by e-mail to **fiapacgrant@exelgyn.com**
 - ▶ All applications must be received by end of December 2021. A reception of email acts as proof of reception.
-

▼ Awarding the grant

- ▶ The Exelgyn/FIAPAC Grant Committee will select the beneficiary.ies according to the quality and originality of the research proposal.
 - ▶ The beneficiary.ies will be informed by an Exelgyn/FIAPAC Grant Committee representative by the end of January 2022. An agreement will be sent to the person in charge of the project. This document will specify the amount and the terms of payment as well as the conditions that need to be fulfilled to receive the grant (expenses proofs, activity reports and evaluation). The notification letters will be sent by e-mail to "the follow-up address" indicated in the file.
 - ▶ The selected project(s) will be published on the FIAPAC website.
 - ▶ The project(s) will be awarded during the next FIAPAC congress.
-

▼ Award deferral

In the event there is an insufficient number of applicants, the committee and the organiser reserve the right to judge the quality's proposal and either defer the final application date, or defer this call for grants to a later date altogether.

▼ Data protection

All personal data (such as names, addresses, CVs, etc.) will be processed in accordance with Regulation (EU) 2016/679 on the General Data Protection of the European Parliament and of the Council on the protection of individuals with regard to the processing of personal data by the European Community institutions and bodies and on the free movement of such data.

Unless marked as optional, the applicant's replies to the questions in the application form are necessary to evaluate and further process the Grant application in accordance with the specifications of the Call for proposals. Personal data will be processed solely for that purpose by the Grant Committee.

Personal data may be transferred on a need to know basis to third parties involved in the evaluation of applications or in the Grant management procedure, without prejudice of transfer to the bodies in charge of monitoring and inspection tasks in accordance with European Union law.

The applicant has the right of access to, and to rectify, the data concerning him or her. For any question relating to these data, please contact Exelgyn/FIAPAC Grant Committee.

They should be paid -up members of the FIAPAC.

▼ Submission of the Grant application

Proposals must be received in accordance with the admissibility requirements section.

No modification to the application are allowed once the deadline for submission has elapsed. However, if there is a need to clarify certain aspects or for the correction of clerical mistakes, the Grant Committee may contact the applicant for this purpose during the evaluation process.

Applicants will be informed in writing about the results of the selection process.

▼ Annexes

Grant application form .